<?xml version="1.0" encoding="UTF-8"?>
<ref id="bjh15394-bib-0019">
 <mixed-citation publication-type="journal" id="bjh15394-cit-0019">
  <string-name>
   <surname>Gupta</surname>, 
   <given-names>N.</given-names>
  </string-name>, 
  <string-name>
   <surname>Labotka</surname>, 
   <given-names>R.</given-names>
  </string-name>, 
  <string-name>
   <surname>Liu</surname>, 
   <given-names>G.</given-names>
  </string-name>, 
  <string-name>
   <surname>Hui</surname>, 
   <given-names>A.M.</given-names>
  </string-name> &amp; 
  <string-name>
   <surname>Venkatakrishnan</surname>, 
   <given-names>K.</given-names>
  </string-name> (
  <year>2016b</year>) 
  <article-title>Exposure‐safety‐efficacy analysis of single‐agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study</article-title>. 
  <source xml:lang="en">Investigational New Drugs</source>, 
  <volume>34</volume>, 
  <fpage>338</fpage>–
  <lpage>346</lpage>.
  <pub-id pub-id-type="pmid">27039387</pub-id>
 </mixed-citation>
</ref>
